Company Profile

Year Established : 2011
Total Assets(USD) : 500,000 to 99,999,999
Total Number of Staff : 100-500
Main Competitive Advantages : Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Patents and Copyrights : 3 Patents
  • Contact Person :
  • Fax:
Harbin Jixianglong Biotech Co., Ltd. is a is a professional high-tech company specializing in R&D and production of polypeptide pharmaceuticals. Our advanced industry chain occupied in R&D, approbation and industrialization of peptides API and preparation. We are honored to be National High-tech Enterprise, Heilongjiang Province Small And Medium-Sized Sci-Tech Enterprise, Heilongjiang Province Innovation Center of Synthetic Peptide, Harbin Enterprise Technology Center. As well as a initiating and governing unit of Peptide Society of China Biochemical Pharmaceutical Industry Association(CBPIA-PS). Founded in 2011, located in Harbin China. With registered capital 17.4291 million, covering an area of 23,000 square meters, construction area 4,000 square meters. Jixianglong has peptide drug production workshop and pilot workshop for personalized cancer neoantigen peptide vaccine which approved by GMP standard. More than 300 sets advanced instruments for production and testing, such as Solid phase synthesizer, Preparative liquid chromatograph, Freeze dryer, High performance liquid chromatograph etc. Main products: Eptifibatide, Somatostatin, Terlipressin Acetate, Thymalfasin, Atosiban Acetate, Carbetocin, Oxytocin, Ganirelix Acetate, Octreotide Acetate, Cetrorelix Acetate, Teriparatide, Bivalirudin, Liraglutide, Nesiritide, Abaloparatide, Semaglutide, tirzepatide,Personalized cancer neoantigen peptide vaccine, Anti Coronavirus peptide bacteriostatic product, Peptide drug conjugate (PDC)
PharmaSources Customer Service